DexCom, Inc. to Post FY2019 Earnings of $1.25 Per Share, Piper Jaffray Companies Forecasts (NASDAQ:DXCM)

Share on StockTwits

DexCom, Inc. (NASDAQ:DXCM) – Analysts at Piper Jaffray Companies issued their FY2019 earnings per share (EPS) estimates for DexCom in a research report issued to clients and investors on Monday, November 18th. Piper Jaffray Companies analyst J. Mckim forecasts that the medical device company will post earnings of $1.25 per share for the year. Piper Jaffray Companies has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for DexCom’s Q4 2019 earnings at $0.55 EPS, Q1 2020 earnings at $0.11 EPS, Q2 2020 earnings at $0.24 EPS, Q3 2020 earnings at $0.71 EPS, Q4 2020 earnings at $0.71 EPS, FY2020 earnings at $1.78 EPS, Q1 2021 earnings at $0.23 EPS, Q2 2021 earnings at $0.40 EPS, Q3 2021 earnings at $0.97 EPS and FY2021 earnings at $2.60 EPS.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The company had revenue of $396.30 million during the quarter, compared to the consensus estimate of $348.99 million. During the same quarter in the prior year, the firm posted $0.17 EPS. The firm’s quarterly revenue was up 48.6% on a year-over-year basis.

Several other equities analysts have also recently issued reports on DXCM. Raymond James upped their price target on shares of DexCom from $172.00 to $189.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $154.00 price objective on the stock in a research note on Friday, October 25th. BTIG Research reaffirmed a “hold” rating on shares of DexCom in a research note on Thursday, August 1st. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $215.00 price objective (up from $190.00) on shares of DexCom in a research note on Thursday, November 7th. Finally, Robert W. Baird upped their price objective on shares of DexCom from $195.00 to $240.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $190.67.

Shares of DexCom stock opened at $221.33 on Thursday. The company has a 50 day moving average of $167.84 and a 200-day moving average of $151.11. The company has a market cap of $19.07 billion, a PE ratio of 737.77 and a beta of 0.64. DexCom has a 1-year low of $105.05 and a 1-year high of $223.25. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41.

A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. Cortina Asset Management LLC bought a new position in shares of DexCom in the second quarter valued at $263,000. Sanders Morris Harris LLC bought a new position in shares of DexCom in the second quarter valued at $759,000. Campbell & CO Investment Adviser LLC bought a new position in shares of DexCom in the second quarter valued at $479,000. Chicago Capital LLC lifted its stake in shares of DexCom by 1.2% in the second quarter. Chicago Capital LLC now owns 194,673 shares of the medical device company’s stock valued at $29,170,000 after buying an additional 2,357 shares in the last quarter. Finally, Patten & Patten Inc. TN lifted its stake in shares of DexCom by 17.4% in the second quarter. Patten & Patten Inc. TN now owns 13,708 shares of the medical device company’s stock valued at $2,054,000 after buying an additional 2,035 shares in the last quarter. 98.21% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Richard Doubleday sold 2,016 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $175.14, for a total transaction of $353,082.24. Following the transaction, the executive vice president now directly owns 72,570 shares of the company’s stock, valued at $12,709,909.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $145.49, for a total transaction of $175,751.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,222 shares of company stock worth $14,846,206. 0.88% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: What is the Hang Seng index?  

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Worthington Industries, Inc.  Expected to Post Earnings of $0.58 Per Share
Worthington Industries, Inc. Expected to Post Earnings of $0.58 Per Share
Brady  Shares Cross Above 50-Day Moving Average of $14.92
Brady Shares Cross Above 50-Day Moving Average of $14.92
FitLife Brands  Shares Cross Above 50 Day Moving Average of $11.54
FitLife Brands Shares Cross Above 50 Day Moving Average of $11.54
HP Inc.  To Go Ex-Dividend on December 10th
HP Inc. To Go Ex-Dividend on December 10th
Brokerages Expect Zebra Technologies  to Post $3.65 EPS
Brokerages Expect Zebra Technologies to Post $3.65 EPS
Crinetics Pharmaceuticals Inc  Expected to Announce Earnings of -$0.67 Per Share
Crinetics Pharmaceuticals Inc Expected to Announce Earnings of -$0.67 Per Share


© 2006-2019 Ticker Report